Inventurus Knowledge Solutions Limited Confirms No Impact of New H-1B Visa Fee Changes

Business Wire India

Inventurus Knowledge Solutions Limited (IKS), a leading care enablement platform, has issued a statement to clarify its position regarding the recently announced changes to the H-1B visa fee structure.

The strategic business model is centered on delivering high-quality, scalable solutions through a robust delivery framework that combines proprietary technology, a highly skilled workforce in India, and a strong commitment to local hiring in the United States. H-1B visas are not integral to the execution of our core business operations or client service delivery. Consequently, the recent changes have no impact on our ability to serve clients, ensure operational continuity, or pursue our long-term growth objectives.

IKS remains committed to its strategy of driving value for clients through deep domain expertise, technology-led solutions, and a robust global delivery framework. We will continue to monitor developments in the global regulatory landscape and provide updates to our stakeholders as necessary.

About IKS Health

IKS Health takes on the chores of healthcare—spanning administrative, clinical, and operational burdens—so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health’s Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health’s global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit ikshealth.com

Inventurus Knowledge Solutions Limited is listed on National Stock Exchange of India Limited (NSE) and BSE Limited (Bombay Stock Exchange). {Scrip codes: NSE - IKS and BSE - 544309}